SOLARA Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹346 Cr
verified against source
Revenue YoY
15%
reported change
EBITDA
₹37 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Solara Active Pharma Sciences reported Q3 FY26 revenue of 346 crores (up 10% QoQ, 15% YoY), but EBITDA collapsed to 37 crores (11% margin) due to severe headwinds in the ibuprofen API business. The company disclosed for the first time that its ibuprofen operations run at just 21% gross margin despite selling 15-17% above competition, with 10,000-12,000 MT capacity but only ~3,000 MT utilization. Management has appointed external advisors to evaluate strategic options including potential sale or shutdown of ibuprofen assets. In contrast, the non-ibuprofen Growth API business (including IBU derivatives) delivers 56% gross margins and 25% EBITDA margins, validating the pivot strategy. A one-time 6.7 crore charge from new labor code provisions further compressed margins. Debt reduced by 146 crores (19%), with a target to bring it below 500 crores by May 2026. The strategic review conclusion is expected with Q4 FY26 results.
Colored figures show movement against the previous available record.
Guidance to track
- Management has line of sight to reduce closing debt below 500 crores post receipt of final regulatory comments, building on the 146 crore reduction already achieved.
- Mothballed Visak facility (FDA-approved) to be converted from single-product ibuprofen plant to multi-purpose plant with a high-potent API block, targeting commercial production revival within 5-6 months.
- External advisor recommendations on ibuprofen business (including sale, cost restructuring, or technical intervention) to be presented alongside Q4 FY26 results by end of April.
Risks flagged
- Management delayed all corporate actions and deferred the planned Visak demerger while evaluating ibuprofen options. The strategic review outcome remains unknown, creating material uncertainty around the company's future structure and capital allocation.
- Analyst Anupam Chan directly questioned why ibuprofen numbers were not disclosed earlier, noting gross margins have dropped 800 basis points between last year and this year. Management acknowledged this is the lowest gross margin reported in recent quarters.
- Arun disclosed that Solara can now only sell ibuprofen to Big Pharma customers, limiting addressable market. These marquee customers are aware of Solara's cost disadvantage and have aligned with current pricing, suggesting limited room for margin recovery.
- When asked about FY27 growth targets for the API growth business and the One Source product launch revenue opportunity, management explicitly declined to provide specifics, stating they will share guidance along with the ibuprofen decision.
Key quotes
- We sell our gross margin at 21% in spite of us selling the product at at least 15 to 17% greater than our competition because we sell to Big Pharma and they are completely aware of the situation and are aligned with our current pricing.
- The ibuprofen derivatives is a very significant business for us and it is a growing business. It's part of the growth business. What we talk about ibuprofen is the ibuprofen plain raw material.
- The fundamentals of our business remain strong. I do firmly believe that we have a resilient operating model, a very robust compliance framework and a diversified portfolio across key markets.
Research modules